Break Wave
Fragmentation of kidney stones
ApprovedActive
Key Facts
About SonoMotion
SonoMotion is a private medical device company pioneering office-based, non-invasive treatments for kidney stone disease. Its platform, featuring the FDA-cleared Break Wave lithotripsy device and the Stone Clear fragment repositioning system, targets a significant procedural market by eliminating the need for general anesthesia and operating room settings. Backed by over $38 million in funding and key regulatory milestones like FDA Breakthrough Device designation, the company is positioned to disrupt the standard of care for a highly prevalent condition.
View full company profile